The Switzerland-based pharmaceutical group Roche reported today, before trading started in Europe, a positive quarter, especially thanks to its new drugs. Sales in the first three months of the year totaled CHF13.58bn (+6%). Performances from the new multiple sclerosis drug Ocrevus were fairly positive, with sales of CHF479m, fairly exceeding analysts’ expectations. On the contrary, analysts were disappointed by the cancer drug Tecentriq, which generated approximately CHF139m sales. Expectedly, an 8% plunge came from cancer blockbuster MabThera, which lost significant market shares due to competition by cheaper biosimilars. On the occasion, the group’s new CEO Severin Schwan has improved the current year guidances (+8%).